Bryce Point Capital, LLC Amicus Therapeutics, Inc. Transaction History
Bryce Point Capital, LLC
- $133 Billion
- Q1 2025
A detailed history of Bryce Point Capital, LLC transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 12,282 shares of FOLD stock, worth $80,201. This represents 0.08% of its overall portfolio holdings.
Number of Shares
12,282Holding current value
$80,201% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding FOLD
# of Institutions
302Shares Held
279MCall Options Held
467KPut Options Held
515K-
Vanguard Group Inc Valley Forge, PA29.3MShares$191 Million0.0% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$159 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY24.2MShares$158 Million7.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY23.2MShares$151 Million3.18% of portfolio
-
William Blair Investment Management, LLC Chicago, IL15.6MShares$102 Million0.38% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $1.83B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...